BioNTech SE BNTX
Rating
Rating Factors
Company Overview
BioNTech SE is a biotechnology company focused on the discovery, development, and commercialization of novel immunotherapies and vaccines based on messenger RNA (mRNA) and other next-generation platforms. The company operates primarily in the biotechnology and pharmaceutical industries, with a strategic emphasis on oncology, infectious diseases, and immunology. BioNTech’s principal revenue driver to date has been its collaboration with Pfizer Inc. for the development and commercialization of the COVID‑19 mRNA vaccine, which established the company as a leading global player in mRNA-based medicines.
Founded in 2008, BioNTech evolved from a research-driven startup into a fully integrated biotechnology company with in-house research, clinical development, manufacturing, and commercialization capabilities. Its unique positioning stems from deep expertise in mRNA technology, a broad intellectual property portfolio, and vertically integrated manufacturing infrastructure, enabling rapid translation of scientific discoveries into clinical and commercial products.
Income Statement
Balance Sheet
Cash Flow
Filings
Price History
- Low
- $79.52
- Current
- $98.57
- High
- $124.00
Valuation
Dividends and Shares
Corporate Info
Mainz, 55131